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Background: The inhibitory mechanism of Aβ42 
aggregation by flavonoid is fully unknown. 
Results: The oxidant enhanced the inhibitory 
activity of (+)-taxifolin against Aβ42 aggregation 
by forming Aβ42-taxifolin adducts between the 
Lys-residues and oxidized (+)-taxifolin. 
Conclusion: The inhibitory activity of 
catechol-type flavonoids requires auto-oxidation 
to form an o-quinone to react with Lys. 
Significance: These may help design promising 
inhibitors against Aβ42 aggregation for 
Alzheimer's therapy. (60<60 words) 
 
SUMMARY (239<250 words) 
The aggregation of 42-residue amyloid 
β-protein (Aβ42) is involved in the 
pathogenesis of Alzheimer's disease (AD).  
Numerous flavonoids exhibit inhibitory 
activity against Aβ42 aggregation, but their 
mechanism remains unclear in molecular level.  
Here we propose the site-specific inhibitory 
mechanism of (+)-taxifolin, a catechol-type 
flavonoid, whose 3',4'-dihydroxyl groups of the 
B-ring plays a critical role.  Addition of 
sodium periodate, an oxidant, strengthened 
suppression of Aβ42 aggregation by 
(+)-taxifolin, whereas no inhibition was 
observed under anaerobic conditions, 
suggesting the inhibition to be associated with 
the oxidation to form o-quinone.  Since the 
formation of Aβ42-taxifolin adduct was 
suggested by mass spectrometry, Aβ42 
mutants substituted at Arg5, Lys16, and/or 
Lys28 with norleucine (nL) were prepared to 
identify the residues involved in the conjugate 
formation.  (+)-Taxifolin did not suppress the 
aggregation of Aβ42 mutants at Lys16 and/or 
Lys28 except for the mutant at Arg5.  In 
addition, the aggregation of Aβ42 was 
inhibited by other catechol-type flavonoids, 
while that of K16nL-Aβ42 was not.  In 
contrast, some non-catechol-type flavonoids 
suppressed the aggregation of K16nL-Aβ42 as 
well as Aβ42.  Furthermore, interaction of 
(+)-taxifolin with β-sheet region in Aβ42 was 
not observed using solid-state NMR unlike 
curcumin of non-catechol-type.  These results 
demonstrate that catechol-type flavonoids 
could specifically suppress Aβ42 aggregation 
by targeting Lys-residues.  Although the 
anti-AD activity of flavonoids has been 
ascribed to their anti-oxidative activity, the 
mechanism that the o-quinone reacts with 
Lys-residues of Aβ42 might be more intrinsic.  




Alzheimer's disease (AD) is characterized by 
amyloid deposition in senile plaques mainly 
consisting of 40- and 42-mer amyloid β-proteins 
(Aβ40, Aβ42) (1,2).  These proteins are 
generated from the amyloid precursor protein by 
β- and γ-secretases (amyloidogenic pathway).  
Aβ aggregates mainly through intermolecular 
β-sheet formation and shows neurotoxicity in 
vitro (3).  Aβ42 plays a more pivotal role in the 
pathogenesis of AD than Aβ40 because of its 
higher aggregative ability and neurotoxicity (3).  
It has been well documented that soluble Aβ 
oligomeric assemblies rather than insoluble fibrils 
cause memory loss and neuronal death (4,5).  
Oxidative stress is one of the major contributing 
factors to neurodegenerative disease progression 
(6).  Aβ-induced toxicity has been correlated to 
oxidative damage through protein radicalization 
in vitro (7,8) and in vivo (9,10).   
Researchers have reported protective effects 
of various polyphenols from green tea, turmeric, 
and red wine etc., against Aβ aggregation and 
neurotoxicity (11-13).  Several compounds [e.g. 
(-)-epigallocatechin-3-gallate (EGCG), curcumin, 
and resveratorol] are in clinical or preclinical 
trials for AD treatment (14,15).  However, the 
recent failures of some trials (16) motivated us to 
clarify the mechanism by which polyphenols 
inhibit the aggregation of Aβ42 to develop 
promising leads for clinical use.   
Concerning the molecular interaction of Aβ 
with flavonoids, a docking simulation by Keshet 
et al. predicted the involvement of Lys28 and the 
C-terminal region in the binding with myricetin 
(17).  However, the precise mode of binding 
with flavonoids has scarcely been addressed, 
except for limited studies using NMR 
spectroscopy [curcumin (18), EGCG (19), and 
myricetin (20)], which suggested less-specific 
interaction with the β-sheet region in Aβ.   
Our group recently found that silymarin, seed 
extracts of Silybum marianum, attenuated AD-like 
pathologic features, such as senile plaques, 
neuroinflammation, behavioral dysfunction, and 
Aβ oligomer formation using a well-established 
AD mouse model (J20) (21).  We also isolated 
(+)-taxifolin (22), a flavanonol which has a 
catechol moiety on the B-ring (Fig. 1A), as a 
component of the extracts that prevents Aβ42 
aggregation (23).  “Aggregation” used in this 
paper means the process of Aβ42 monomer to 
form fibrils by way of oligomer and/or protofibril.  
This paper describes a comprehensive study on 
the ability of (+)-taxifolin to prevent aggregation 
and β-sheet formation of Aβ42, along with the 
effects of various flavanonols and flavonols on 
the aggregation of Aβ42 mutants substituted at 
Arg5, Lys16, and/or Lys28 with norleucine (nL).  
These results together with the results of liquid 
chromatography-mass spectrometry (LC-MS) led 
us to propose a site-specific inhibitory mechanism 
for Aβ42 aggregation by catechol-type flavonoids, 
where adduct formation at the Lys-residues in 
Aβ42 with the o-quione derived from flavonoids 





Synthesis of (+)-Taxifolin, Dihydrokaempferol 
and Pinobanksin— A naturally-occurring form of 
(+)-taxifolin was synthesized (Scheme S1A in 
Supplemental Data) basically according to the 
previous reports (23,24).  Briefly, vanillin was 
demethylated by treatment with boron tribromide 
to give 3,4-dihydroxybenzaldehyde quantitatively, 
whose phenolic hydroxyl groups were protected 
with methoxymethyl groups.  The phenolic 
hydroxyl groups of 2,4,6-trihydroxyacetophenone 
were also protected with methoxymethyl groups.  
A cross-aldol reaction between these products, 
followed by treatment with H2O2 under a basic 
condition, yielded the epoxide 7 (supplemental 
Scheme S1A), which was cyclized and 
deprotected under an acidic condition to give 
(±)-taxifolin.  (+)-Taxifolin was separated by 
HPLC on a CHIRALCEL OJ-RH column (10 mm 
i.d. x 150 mm; Daicel Corporation, Osaka, Japan) 
using 15% CH3CN/H2O containing 0.1 % acetic 
acid (25).  Synthesis of 13C6-(+)-taxifolin was 
performed by using vanillin-ring-13C6 (Isotec, 
Miamisburg, OH) as a starting material.   
(±)-Dihydrokaempferol (26) and 
(±)-pinobanksin (27) were synthesized in a 
manner similar to (±)-taxifolin using 
4-hydroxybenzaldehyde or benzaldehyde in place 
of vanillin as a starting material, respectively 
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(supplemental Scheme S1A).  Enantiomers were 
not separated because the inhibitory effect on 
Aβ42 aggregation by (–)-taxifolin was almost the 
same as that by (+)-taxifolin (23).  The structure 
of each of these compounds was confirmed by 1H 
NMR (AVANCE III 500, ref. TMS, Bruker, 
Germany) and EI-MS (JMS-600H, JEOL, Tokyo, 
Japan).  EI-MS data were as follows: 
(+)-taxifolin (m/z 304 [M]+), 13C6-(+)-taxifolin 
(m/z 310 [M]+), dihydrokaempferol (m/z 288 
[M]+), and pinobanksin (m/z 272 [M]+).  The 
spectra of 1H NMR (28) and 13C NMR (29) of 
13C6-(+)-taxifolin are shown in supplemental Fig. 
S1.  The optical rotation of each enantiomer 
was; (+)-taxifolin [α]D +17.3 (c 0.1, MeOH), 
(–)-taxifolin [α]D –16.2 (c 0.1, MeOH), almost 
equal to those reported previously; (+)-taxifolin 
[α]D +19.0 (c 0.1, MeOH) (22).  Other 
flavonoids; myricetin (Wako, Osaka, Japan), 
kaempferol, (±)-dihydromyricetin (ChromaDex, 
Irvine, CA), morin, galangin, quercetin (Sigma, St. 
Louis, MO), and datiscetin (Extrasynthese, Genay, 
France) were purchased commercially.   
 
Trapping of the o-Quinone Form of 
(+)-Taxifolin by Phenylenediamine―Sodium 
periodate (NaIO4, 19 mg, 89 µmol) in H2O (0.20 
mL) was added to (±)-taxifolin (28 mg, 91 µmol; 
Toronto Research Chemicals Inc. North York, 
ON, Canada) in methanol (3.5 mL).  After 
stirring for 15 min at room temperature, the 
reaction mixture was extracted with ethyl acetate 
(5.0 mL), to which 1,2-phenylenediamine (9.8 mg, 
91 µmol; Wako) was added before stirring for 30 
min at room temperature.  The mixture was 
concentrated and separated by HPLC on a YMC 
SH-342-5AL column (20 mm i.d. x 150 mm; 
YMC, Kyoto, Japan) with 60% MeOH/H2O to 
give the corresponding phenazine (3.8%) 
(supplemental Scheme S1B).  The structure was 
confirmed by 1H NMR and high resolution 
(HR)-EI-MS.  1H NMR (500 MHz, 295.3 K, 
acetone-d6, 6.98 mM) δ 4.87 (1H, d, J = 11.5 Hz), 
5.59 (1H, d, J = 11.5 Hz), 6.07 (1H, s), 6.09 (1H, 
s), 7.96-8.00 (2H, m), 8.22 (1H, dd, J = 9.0, 1.7 
Hz), 8.26-8.30 (2H, m), 8.33 (1H, d, J = 9.0 Hz), 
8.46 (1H, d, J = 1.7 Hz), 11.72 (1H, brs); 
HR-EI-MS m/z 374.0902 [M]+, calcd for 
C21H14N2O5 374.0903. 
 
Thioflavin-T Fluorescence Assay―The 
aggregative ability of Aβ42 was evaluated at 37 
oC by the thioflavin-T (Th-T) method developed 
by Naiki et al (30).  The procedure was 
described elsewhere (31).  Fluorescence 
intensity was measured at 420 nm excitation and 
485 nm emission using a micro-plate reader 
(MPR-A4ιII; TOSOH, Tokyo, Japan, or 
Fluoroskan Ascent; Thermo Scientific, Rockford, 
IL).  In brief, Aβ42 was dissolved in 0.1% 
NH4OH at 250 µM, and each flavonoid was 
dissolved in EtOH at 5 mM, followed by dilution 
with sodium phosphate-buffered saline (PBS: 50 
mM sodium phosphate and 100 mM NaCl, pH 
7.4) at the desired concentration (Aβ42, 25 µM; 
flavonoids, 50 µM).  NaIO4 or 
Tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP-HCl) was initially dissolved in PBS at 100 
mM, then diluted with PBS at 100 µM before use.  
Experiments under an anaerobic condition were 
performed in a desiccator evacuated by a 
diaphragm pump (ca. 8 mmHg; KNF Lab 
LABOPORT vacuum pump, KNF Neuberger, NJ) 
at room temperature.  Unless otherwise noted, 
the concentrations of Aβ42, flavonoids, and 
oxidant/reductant used in this study were 25, 50, 
and 100 µM, respectively. 
The effect of the addition of NaIO4 on Met35 
oxidation was estimated by HPLC on a Develosil 
ODS UG-5 column (6.0 mm i.d. x 100 mm; 
Nomura chemical, Seto, Japan) under a gradient 
of 10-50% CH3CN containing 0.1% NH4OH for 
40 min after the centrifugation of the Aβ42 
solution at 20,130 g at 4 oC (MX-300; TOMY, 
Tokyo, Japan) for 10 min. 
The seeds of Aβ42 were also prepared 
basically according to the protocol developed by 
Naiki et al (30).  Briefly, after incubation of 
Aβ42 (25 µM) in PBS (pH 7.4) for 24 h at 37 oC, 
the pellet obtained by centrifugation at 20,130 g 
at 4 oC for 1 h was suspended by pipetting in PBS 
(pH 7.4) at concentration of 1 mg/mL.  The 
resultant solution was sonicated for 1 h in an 
ultrasonic device (MUS-20; EYELA, Tokyo, 
Japan), followed by dilution with PBS at 10 
µg/mL before use.  Th-T relative fluorescence 
was expressed as a percentage of wild-type Aβ42 
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alone, whose maximum value was taken as 100%. 
 
Transmission Electron Microscopy 
(TEM)―The aggregates of Aβ42 after a 48-h 
incubation were examined under a H-7650 
electron microscope (Hitachi, Ibaraki, Japan).  
The experimental procedure was described 
elsewhere (31). 
 
UV-visible Spectrometry―Oxidation of 
(+)-taxifolin was monitored by UV spectroscopy 
(UV-2200A; Shimadzu, Kyoto, Japan).  
(+)-Taxifolin (50 µM) was incubated with Aβ42 
(25 µM) in PBS (50 mM sodium phosphate and 
100 mM NaCl, pH 7.4) at 37 oC.  The solution 
was then loaded into a 1-cm path length quartz 
cell, and UV spectra were recorded at 200-500 nm.  
The sample was diluted three times with PBS 
because of its strong absorbance. 
 
Circular Dichroism (CD) Spectrometry―The 
secondary structure of Aβ42 was estimated by CD 
spectrometry (J-805; JASCO, Tokyo, Japan) 
using a 0.1-mm quartz cell (121.027-QS, φ 10 
mm; JASCO), as described elsewhere (32).   
Aβ42 (25 µM) was incubated with or without 
(+)-taxifolin (50 µM) in PBS (50 mM sodium 
phosphate and 100 mM NaCl, pH 7.4) at 37 oC.  
An aliquot was loaded into the quartz cell, and 
CD spectra were recorded at 190-250 nm.  
Experiments under an anaerobic condition were 
performed as described before.  The spectra of 
Aβ42 mutants are shown after subtraction of the 
spectrum for vehicle alone, and those in the 
presence of (+)-taxifolin are shown after 
subtraction of the spectrum for (+)-taxifolin 
alone. 
 
LC-MS Analysis―Aβ42 solution (25 µM) 
was incubated with 50 µM (+)-taxifolin in PBS 
(50 mM sodium phosphate and 100 mM NaCl, 
pH 7.4) in the presence of 100 µM NaIO4 at 37 oC.  
After a 4-h incubation, the mixture was desalted 
and condensed twice by ZipTip C18 (Millipore, 
Bedford, MA).  Five microliters of the solution 
was subjected to a liquid chromatography mass 
spectrometry ion trap time-of-flight 
(LCMS-IT-TOF; Shimadzu) through a 
YMC-Pack ODS-AQ column (6.0 mm i.d. x 100 
mm; YMC) at 25 oC under a gradient of 20-60% 
CH3CN containing 0.1% formic acid for 30 min. 
 
Synthesis of Aβ42 Mutants―  
Fmoc-norleucine (nL)-OH was purchased from 
Watanabe Chemical Industries (Hiroshima, 
Japan).  L-Alanine (13C3, 15N), L-phenylalanine 
(13Cβ), and L-valine (13C5, 15N) were purchased 
from Isotec, and L-lysine (13C6, 15N2) and L-serine 
(13C3, 15N) from Cambridge Isotope Laboratories 
(Frontage Road Andover, MA).  Each labeled 
amino acid was protected by an Fmoc group as 
previously reported (33,34).  The structure of 
each Fmoc derivative was confirmed by 1H NMR, 
13C NMR, and FAB-MS.   
The Aβ42 mutants were synthesized in a 
stepwise fashion on 0.1 mmol of preloaded 
Fmoc-L-Ala-PEG-PS resin using a PioneerTM 
Peptide Synthesizer (Applied Biosystems, Foster 
City, CA) as reported previously (35).  After the 
chain elongation was completed, the peptide-resin 
was treated with a cocktail containing 
trifluoroacetic acid, m-cresol, thioanisol, and 
1,2-ethanedithiol for final deprotection and 
cleavage from the resin.  The crude peptide was 
precipitated by diethylether and purified by HPLC 
under an alkaline condition as described 
previously (31).  After lyophilization, we 
obtained the corresponding pure Aβ42 peptide, 
the purity of which was confirmed by HPLC 
(>98%).  The molecular weight of each Aβ42 
mutant was confirmed by matrix-assisted laser 
desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS, AXIMA-CFR; 
Shimadzu); R5nL-Aβ42 (m/z, calcd: 4472.11, 
found: 4472.38 [M+H]+), K16nL-Aβ42 (m/z, 
calcd: 4500.12, found: 4500.25 [M+H]+), 
K28nL-Aβ42 (m/z, calcd: 4500.12, found: 
4500.32 [M+H]+), K16,K28(nL)2-Aβ42 (m/z, 
calcd: 4485.11, found: 4485.13 [M+H]+), 
R5,K16,K28(nL)3-Aβ42 (m/z, calcd: 4442.08, 
found: 4442.58 [M+H]+), 13C,15N labeled-Aβ42 
(m/z, calcd: 4538.90, found: 4538.94 [M+H]+). 
  
Solid-state NMR Analysis―Aβ42 was labeled 
at Ala2 (13C3, 15N), Ser8 (13C3, 15N), Lys16 (13C6, 
15N2), Val18 (13C5, 15N), Phe19, and Phe20 (13Cβ).  
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(+)-Taxifolin was labeled with 13C6 on the B-ring 
as mentioned above (23,24).  The labeled Aβ42 
(13 µM) was incubated with 13C6-(+)-taxifolin 
(145 µM) in PBS (50 mM sodium phosphate and 
100 mM NaCl, pH 7.4) at 37 oC.  After 48 h of 
incubation, the solution was centrifuged (27,720 g,  
PRP-20-2; Hitachi) for 15 min at 4 oC, and then 
the precipitate was dried in vacuo to give the 
labeled Aβ42 aggregate associated with 
13C6-(+)-taxifolin (12 mg).  The solid-state NMR 
experiments were performed at 14 T (600 MHz 
for 1H) using a JEOL ECA-600 spectrometer and 
a custom-fabricated probe with a Chemagnetics 
3.2 mm spinning system at a magic angle 
spinning (MAS) frequency of 21 kHz at room 
temperature as reported previously (18).  The 13C 
chemical shifts were calibrated in ppm relative to 
tetramethylsilane by considering the 13C chemical 
shift for methine 13C of solid adamantine (29.5 
ppm) as an external reference.  The 13C chemical 
shifts of labeled Aβ42 and (+)-taxifolin were 
assigned according to 1D-13C CP/MAS NMR 
spectra (supplemental Fig. S2A).  For the 
broadband 13C-13C correlation 2D experiments, 
dipolar-assisted rotational resonance (DARR) was 
used (36).  Pulse sequence parameters of the 
NMR experiment were as follows; two pulse 
phase-modulated (TPPM) 1H decoupling power = 
80 kHz, RAMP-CP contact time = 1.2 ms, pulse 
delay = 2 s, t1 increment = 23.7 µs, t1 points of 2D 
= 128 pt, and mixing time (τm) = 50 ms or 500 
ms.  The window function ‘HAMMING’ was 
used in all 2D FT spectra to minimize t1 noise.  
As the 2D FT DARR spectra were difficult to 
analyze because of the t1 noise (supplemental Fig. 
S2C), we applied covariance data processing to 
obtain a better representation of the 2D spectrum 
(supplemental Fig. S2B).  After Fourier 
transformation along the t2 dimension and phase 
correction, the resulting data matrix was used for 
covariance processing as previously reported 
(18,37).  The covariance processing step was 
accelerated by singular value decomposition (38).   
 
Statistical Analyses―All data are presented as 
the means ± s.e.m. and the differences were 
analyzed with an one-way analysis of variance 
(ANOVA) followed by Bonferroni's test or 
unpaired Student's t-test.  These tests were 
implemented within GraphPad Prism software 





Effects of Auto-oxidation of (+)-Taxifolin on 
Its Ability to Prevent the Aggregation of 
Aβ42―We recently revealed that a catechol 
moiety on the B-ring of (+)-taxifolin (Fig. 1A) 
played important role on the inhibitory activity 
against Aβ42 aggregation (23).  A catechol 
moiety is easily oxidized to form an o-quinone 
(39).  To investigate the contribution of 
auto-oxidation to the inhibitory ability, we 
examined the aggregative ability of Aβ42 in the 
presence of (+)-taxifolin treated with sodium 
periodate (NaIO4), which is known as an oxidant 
of catechol (40).  As shown in Fig. 1B, NaIO4 
extensively promoted the suppressive ability of 
(+)-taxifolin compared with (+)-taxifolin alone.  
These observations were also confirmed by the 
TEM experiment (Fig. 2A).  NaIO4 treatment in 
the presence of (+)-taxifolin formed only shorter 
and thinner fibrils compared with (+)-taxifolin 
alone.  Aβ42 formed the typical fibrils even in 
the presence of NaIO4 alone, and almost no 
differences (e.g. length, thickness) were observed 
between the morphology in the presence and 
absence of NaIO4 (Fig 2A). 
NaIO4 alone slightly affected the Th-T 
fluorescence of Aβ42 aggregates (Fig. 1B) 
possibly because NaIO4 can oxidize Met35 in 
Aβ42 to its sulfoxide, the formation of which was 
confirmed by HPLC (Fig. 1D) and 
MALDI-TOF-MS (Aβ42-M35ox; m/z: calcd: 
4531.14, found: 4531.55 [M+H]+).  This is in 
good agreement with a report that oxidation using 
hydrogen peroxide, a strong oxidant, reduced 
Aβ42 aggregation (41).  However, in the 
presence of both (+)-taxifolin (50 µM) and NaIO4 
(100 µM), Met35 was not oxidized by NaIO4; this 
was confirmed by HPLC (Fig. 1D) and 
MALDI-TOF-MS (Aβ42-M35red; m/z: calcd: 
4515.14, found: 4516.26 [M+H]+).  This 
indicates that NaIO4 preferred to oxidize 
(+)-taxifolin more than the sulfur atom of the 
Met35 of Aβ42.  
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In addition, we tested whether the treatment of 
NaIO4 leads to the oxidation of Met35 in the 
preformed Aβ42 fibrils.  The fibrils (ca. 28 µg) 
treated with NaIO4 for 4 h were dissolved in 
formic acid (10 µL), and were sonicated for 1 h.  
After volatilization, the resultant pellets were 
resolved in 50% acetonitrile containing 0.1% 
trifluoroacetic acid, followed by subjection to 
MALDI-TOF-MS analysis.  NaIO4 did not 
oxidize Met35 in the preformed Aβ42 fibril 
(Aβ42-M35red; m/z: calcd: 4515.14, found: 
4515.12 [M+H]+).  Also in Th-T assay, Aβ42 
fibril was not disassembled by NaIO4 (data not 
shown).  These mean that NaIO4 could partially 
oxidize Met35 in the monomeric Aβ42, but not 
the fibrils. 
In order to investigate the role of oxygen, 
suppression of Aβ42 aggregation by (+)-taxifolin 
was tested in vacuo.  Notably, (+)-taxifolin little 
suppressed the aggregation of Aβ42 under an 
anaerobic condition (Fig. 1C).  In TEM images, 
typical fibril formation was observed even in the 
presence of (+)-taxifolin under the anaerobic 
condition (Fig. 2A).  Furthermore, Aβ42 
aggregated in the presence of (+)-taxifolin and 
tris(2-carboxyethyl)phosphine (TCEP), a 
reductant (Fig. 1E).  These results suggest the 
auto-oxidation of (+)-taxifolin to be required for 
inhibitory activity against Aβ42 aggregation.   
The mechanism of Aβ42 fibril formation is 
well explained by a nucleation-dependent 
polymerization model mainly consisted of 
nucleation phase and extension phase (42,43).  
To determine which stage (nucleation phase or 
extension phase) was affected by (+)-taxifolin, we 
examined the effect of (+)-taxifolin on Aβ42 
aggregation in the presence of the fibril seed as a 
template, according to the protocol developed by 
Naiki et al. (30).  As shown in Fig 1F, there was 
a nucleation phase (~1 h) when Aβ42 was 
incubated alone, whereas addition of the seeds 
skipped the nucleation phase, resulting in the 
rapid formation of Aβ42 fibrils.  In the case of 
co-incubation of (+)-taxifolin with the seeds, the 
nucleation phase of Aβ42 did not drastically 
change, but the fluorescence gradually decreased 
after incubation for 4 h, suggesting that 
(+)-taxifolin could prevent the elongation phase 
(~2 or 4 h) in Aβ42 aggregation, rather than the 
nucleation phase (~1 h) (Fig. 1B, F).  Although 
the slight difference of the length of elongation 
phase between Fig. 1B and 1F might be deduced 
from several factors, for example, outside 
temperature, batch (lot) of Aβ42, 2~4 h as an 
averaged time for elongation phase were observed 
in another independent experiments.  Moreover, 
we have recently reported the ability of 
(+)-taxifolin to destabilize the preformed Aβ42 
fibril (23).  The disappearance of nucleation 
phase in the presence of seed and NaIO4 (Fig. 1F) 
implied the ability of oxidized taxilfolin to 
disassemble even the seed.  Indeed, the 
fluorescence of preformed Aβ42 fibrils 
immediately disappeared after addition of 
(+)-taxifolin treated with NaIO4 (data not shown). 
Next, we measured UV spectra of 
(+)-taxifolin incubated with Aβ42 to evaluate the 
effects of NaIO4 or the anaerobic condition on the 
auto-oxidation of (+)-taxifolin.  When Aβ42 was 
incubated with (+)-taxifolin under air, the 
intensity of the peak at 260 nm and 400 nm 
gradually increased, and that of the peak at 320 
nm decreased during 48 h of incubation (Fig. 2B).  
These spectral changes are characteristic of the 
oxidation of catechol-type flavonoids to form the 
o-quinone structure (44).  The addition of NaIO4 
accelerated these UV changes (Fig. 2B).  In 
contrast, there was almost no change in the UV 
spectra when (+)-taxifolin and Aβ42 were 
co-incubated in vacuo or with TCEP (Fig. 2B).  
These results indicate that the o-quinone 
formation in (+)-taxifolin through auto-oxidation 
plays a critical role in the inhibition of Aβ42 
aggregation.  The UV spectra of Aβ42 alone 
remained almost constant during the incubation 
(data not shown), meaning that the spectra of 
Aβ42 itself did not affect those of (+)-taxifolin.   
Conversion to the o-quinone from 
(±)-taxifolin in the presence of NaIO4 was also 
verified by reacting with o-phenylenediamine to 
yield phenazine (supplemental Scheme S1B), 
whose structure was confirmed by 1H NMR and 
HR-EI-MS.   
 
Effects of Auto-oxidation of (+)-Taxifolin on 
Its Ability to Inhibit Transformation of a Random 
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Structure into a β-Sheet in Aβ42―We 
investigated the effects of auto-oxidation of 
(+)-taxifolin on the secondary structure of Aβ42 
by using CD spectroscopy.  Shown in Fig. 3A is 
the data for Aβ42; the positive peak at 195 nm 
and negative peak at 215 nm drastically increased 
even after 4 h of incubation, and remained until 
48 h of incubation, suggesting that a random 
structure transformed into a β-sheet in Aβ42.  
On the other hand, (+)-taxifolin strongly delayed 
the transformation of Aβ42 (Fig. 3B).  
Furthermore, addition of NaIO4 decelerated the 
transformation process during 0~8 h (Fig. 3C).    
We also measured the CD spectra under an 
anaerobic condition (Fig. 3D, E).  A spectrum 
related to the β-sheet formation was found only 
after 24 h of incubation, but its peak intensity was 
weaker than that of Aβ42 under air in Fig. 3A.  
Since radicalization of Aβ42 induced by reactive 
oxygen species is indispensable to its aggregation 
(8), these results seem to be reasonable.  The 
transformation into a β-sheet was not suppressed 
either by (+)-taxifolin in vacuo.  The findings 
suggest that the effects of auto-oxidation of 
(+)-taxifolin on its ability to inhibit Aβ42 
aggregation are closely associated with 
prevention of the transformation into a β-sheet. 
 
LC-MS Analysis of Aβ42 Treated with 
Oxidized Taxifolin―The o-quinone of flavonoids 
can form covalent bonds with nucleophilic 
residues in proteins (e.g. Cys, Arg, Lys) to 
modulate their activity (39,45).  Because Aβ42 
has three basic amino acid residues (Arg5, Lys16, 
Lys28), we asked if these residues bound to 
oxidized taxifolin covalently.  The o-quinone 
derived from (+)-taxifolin can react with Lys or 
Arg residues in Aβ42 through a Michael addition 
or Schiff base formation (Fig. 4A).  We analyzed 
an Aβ42 solution incubated with (+)-taxifolin and 
NaIO4 for 4 h using a highly sensitive ion trap 
type LC-MS equipped with a TOF mass analyzer 
(LCMS-IT-TOF).  As shown in Fig. 4B, LC-MS 
measurements gave the mass envelop at +7, +6, 
and +5 charge distribution (deconvoluted mass: 
4817.12, calcd: 4816.38), corresponding to the 
Aβ42–oxidized taxifolin adduct resulted from 
Michael addition.  These results imply that the 
basic amino acid residues of Aβ42 might be 
involved in the covalent bonding with the 
oxidized taxifolin.   
 
Inhibitory Effect of (+)-Taxifolin on 
Aggregation of Aβ42 Mutants Substituted at Arg5, 
Lys16, and/or Lys28―Although formation of 
Michael adducts between the o-quinone of 
(+)-taxifolin and the Lys residues of Aβ42 was 
suggested in LC-MS (Fig. 4B) together with the 
verification of the o-quinone formation 
(supplemental Scheme S1B), an attempt to 
determine the Lys residues involved in the adduct 
formation by LC-MS-MS analysis was 
disappointing, possibly because of the extremely 
low amount and/or instability of the adduct.  To 
obtain further insight into the mechanism by 
which (+)-taxifolin inhibits the aggregation of 
Aβ42, we prepared five Aβ42 mutants [R5nL-, 
K16nL-, K28nL-, K16,K28(nL)2-, and 
R5,K16,K28(nL)3-Aβ42], where the basic amino 
acid residues of Aβ42 were substituted with 
norleucine (nL).  The aggregative ability in the 
presence or absence of (+)-taxifolin was also 
estimated (Figs. 5A-E).  These mutants retained 
substantial aggregative abilities to form fibrils 
(70~80%) compared with wild-type Aβ42 in 
Th-T test (Fig. 5F).  (+)-Taxifolin did not 
suppress the aggregative ability of K16nL-Aβ42 
(Fig. 5B).  K28nL-Aβ42 also aggregated in the 
presence of (+)-taxifolin, though intensity of the 
Th-T fluorescence slightly decreased than that for 
K28nL-Aβ42 alone (Fig. 5C).  Moreover, 
(+)-taxifolin did not prevent the aggregation of 
K16,K28(nL)2-Aβ42 and R5,K16,K28(nL)3-Aβ42 
(Figs. 5D and E).  On the other hand, 
(+)-taxifolin largely suppressed the aggregation of 
R5nL-Aβ42 (Fig. 5A). These results indicate that 
lysine residues at positions 16 and 28 could be 
targets for the oxidized taxifolin to prevent the 
aggregation of Aβ42.  More correctly, since the 
aggregative ability of K28nL-Aβ42 was slightly 
suppressed by (+)-taxifolin compared with that of 
K16nL-Aβ42 (Figs. 5B and C), Lys16 would be 
more specific target than Lys28 in inhibition of 
Aβ42 aggregation. 
 




quercetin, morin, and kaempferol, which were 
previously reported to inhibit Aβ42 aggregation, 
belong to the flavonols (43).  Flavonols contain 
a double bond between C2 and C3 on the C-ring, 
whereas flavanonols like (+)-taxifolin do not (Fig. 
6A).  We calculated IC50 for Aβ42 aggregation 
from the inhibitory rate (%) of each flavonoid [10, 
25, 50, 100 µM for a strong-class inhibitor 
(dihydromyricetin, (+)-taxifolin, myricetin, 
quercetin); 25, 50, 100, 250 µM for a 
middle-class inhibitor (morin, kaempferol, 
datiscetin); 50, 100, 250, 500 µM for a weak-class 
inhibitor (dihydrokaempferol, pinobanksin, 
galangin)] on the aggregation of Aβ42 (25 µM) 
after a 24-h incubation.  The values of IC50 were 
summarized in Fig. 6A.  Among flavanonols, 
dihydromyricetin (IC50 = 25.3 µM) as well as 
(+)-taxifolin (IC50 = 33.0 µM) with contiguous 
hydroxyl groups on the B-ring suppressed the 
aggregation of Aβ42, whereas dihydrokaempferol 
and pinobanksin (IC50 >500 µM) with one or no 
hydroxyl group did not (Fig. 6A), suggesting 
vicinal hydroxyl groups on the B-ring to be 
essential for the inhibitory activity of flavanonols.  
Similarly, among flavonols, we compared the 
ability to inhibit Aβ42 aggregation of myricetin, 
quercetin, morin, kaempferol, datiscetin, and 
galangin.  The aggregation of Aβ42 was strongly 
suppressed by myricetin (IC50 = 15.1 µM) and 
quercetin (IC50 = 15.3 µM) with vicinal hydroxyl 
groups on the B-ring, while galangin (IC50 >500 
µM) without a hydroxyl group on the B-ring did 
not show any inhibitory activity (Fig. 6A).  
Interestingly, morin (IC50 = 30.3 µM), kaempferol 
(IC50 = 75.1 µM), and datiscetin (IC50 = 55.4 µM) 
without a catechol moiety moderately suppressed 
the aggregation of Aβ42 (Fig. 6A).  Regarding 
the relevance of auto-oxidation to the inhibition 
of Aβ42 aggregation, we measured the Th-T 
fluorescence of Aβ42 treated with these three 
non-catechol-type flavonols under an anaerobic 
condition or in the presence of TCEP.  All these 
flavonols suppressed the aggregation of Aβ42 
even in vacuo (Fig. 6B).  Moreover, addition of 
excess of TCEP (Aβ42 : flavonols : TCEP = 25 : 
50 : 200 µM) did not affect the suppressive ability 
of these flavonols (data not shown), indicating 
that the inhibition of non-catechol-type flavonols 
could not be ascribed to their auto-oxidation.   
To gain further insight into the mechanism by 
which flavonoids inhibit Aβ42 aggregation by 
targeting the Lys residues, aggregation tests were 
carried out in the presence of catechol-type 
flavonoids (dihydromyricetin, (+)-taxifolin, 
myricetin or quercetin), or non-catechol-type 
flavonols (morin, kaempferol, or datiscetin) using 
K16nL- and K16,K28(nL)2-Aβ42.  We 
compared the aggregative ability of Aβ42 mutant 
(25 µM) incubated with each flavonoid (50 µM), 
the concentration of which was the maximal value 
to suppress the fluorescence of Aβ42 under 50% 
by (+)-taxifolin (data not shown).  The 
catechol-type (+)-taxifolin and quercetin did not 
suppress the aggregation of these Aβ42 mutants.  
Although dihydromyricetin and myricetin with 
contiguous trihydroxyl groups significantly 
prevented the aggregation of K16nL-Aβ42, these 
flavonoids did not change the aggregative potency 
of K16,K28(nL)2-Aβ42 (Fig. 7A), implying that 
they could react with Lys28 as well as Lys16 
because contiguous trihydroxyl groups might 
facilitate the auto-oxidation of the B-ring 
compared with (+)-taxifolin and quercetin 
containing vicinal hydroxyl groups.  Notably, in 
the case of non-catechol-type flavonols (morin, 
kaempferol, and datiscetin), there was little 
difference in the inhibitory activity among the 
wild-type, K16nL-Aβ42, and 
K16,K28(nL)2-Aβ42 (Fig. 7B).  These results 
suggest the existence of another inhibitory 
mechanism for Aβ42 aggregation by 
non-catechol-type flavonols other than the 
auto-oxidation followed by the Michael addition 
of Lys residues, as observed for (+)-taxifolin. 
 
Analysis of the Interaction of Aβ42 
Aggregates with (+)-Taxifolin Using Solid-State 
NMR―Our recent study using a solid-state NMR 
showed that curcumin with an α,β-unsaturated 
ketone interacted with the aromatic hydrophobic 
core (Aβ17-21) due to its inherent hydrophobicity 
and planarity, resulting in the inhibition of Aβ42 
aggregation via intercalation (18).  Curcumin 
was reported to interact with Aβ40 fibrils through 
the planarity of the enol form of curcumin (46).  
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Also given the preferable detection of monomeric 
Aβ42 in LC-MS analysis, similar analysis was 
performed to clarify the interaction between Aβ42 
and (+)-taxifolin.  (+)-Taxifolin was labeled with 
13C6 on the B-ring based on the previous 
structure-activity relationship studies, in which 
the catechol moiety on the B-ring is critical in the 
inhibitory potential, and the methylation of 
hydroxyl group at position 7 on the A-ring did not 
influence the aggregation of Aβ42 (23).  Aβ42 
was also 13C-labeled site-specifically at Ala2, 
Ser8, Lys16, Val18, Phe19, and Phe20, in which 
only Cβ was labeled in Phe19 and Phe20 to avoid 
the overlapping of the signals of Aβ42 and 
(+)-taxifolin.  For the broadband 13C-13C 
correlation 2D experiments, dipolar-assisted 
rotational resonance (DARR) was employed (34).  
As shown in supplemental Fig. S2B, the 
interaction peaks between Aβ42 and (+)-taxifolin 
were as weak as noise signals despite of the use of 
a ten-fold excess of (+)-taxifolin (Aβ42 : 
(+)-taxifolin = 13 : 145 µM), while a five-fold 
excess was employed for curcumin (Aβ42 : 
curcumin = 10 : 50 µM) (18).  Remarkably, the 
13C-13C cross peaks between Lys-residues and 
B-ring of (+)-taxifolin was not observed 
significantly (Supplemental Fig. S2B).  More 
specifically, the interaction of (+)-taxifolin with 
the aromatic hydrophobic core (Aβ17-21), which 
was previously found in the curcumin case due to 
its inherent hydrophobicity and planarity (18) was 
not observed.  These indicate that the inhibitory 
mechanism of Aβ42 aggregation by (+)-taxifolin 
(via covalent bonding) could be different from 
that of curcumin (via intercalation).   
Since lack of the double bond at positions 2 
and 3 of (+)-taxifolin could decreases its planarity, 
it might not be able to insert into the β-sheet 
region of the Aβ42 aggregate (Lys16~Ala21).  
Instability of the oxidized taxifolin–Aβ42 adduct 
might be another reason.  The previous 
solution-state NMR studies on myricetin and 
Aβ42 (20) suggested the less-specific broad 
recognition of the β-sheet region, possibly due to 
the usage of excessive amounts of myricetin 
(Aβ42 : myricetin = 25 : 200 µM).  This finding 
might reflect the difference in suppressive ability 
between myricetin and (+)-taxifolin against 




Thus far, the anti-AD activity of flavonoids 
has been believed to originate from their 
anti-oxidative activity and/or β-sheet recognition 
due to their hydrophobicity and planarity.  
However, these parameters are not necessarily 
accompanied by the ability to inhibit the 
aggregation of Aβ42 and other amyloidogenic 
proteins (11).  This background led us to 
reconsider whether the inhibitory activity can be 
simply explained by these “less-specific” 
properties (anti-oxidation, hydrophobicity, and 
planarity) or not.   
On the basis of the present results, we propose 
a site-specific mechanism whereby catechol-type 
flavonoids inhibit the aggregation of Aβ42, in 
which a catechol structure could be auto-oxidized 
to form the o-quinone on the B-ring, followed by 
the formation of the o-quinone-Aβ42 adduct 
targeting Lys residues at positions 16 and 28 of 
Aβ42, but not be originated from the 
anti-oxidative activity (Fig. 8).  This could 
provide unique opportunities to design potent 
inhibitors of Aβ42 aggregation.  On the other 
hand, the inhibitory ability of non-catechol-type 
flavonols containing a double bond between C2 
and C3 on the C-ring (Fig. 6A) does not require 
the auto-oxidation.  The data in Figs. 6 and 7 
indicate that the interaction of non-catechol-type 
flavonols with Aβ42 might be less effective than 
the conjugate addition of the Lys residues to the 
o-quinone moiety derived from auto-oxidation.  
These findings might explain in part the 
difference in the inhibitory ability between 
flavanonols and flavonols. 
Our previous investigation using solid-state 
NMR together with systematic proline 
replacement identified a toxic conformer with a 
turn at positions 22 and 23 in Aβ42 (47), and 
proposed that the residues at positions 15-21 and 
24-32 containing Lys 16 and Lys 28 are involved 
in the intermolecular β-sheet region, whereas the 
N-terminal 13 residues are not (48).  A 
monoclonal antibody against the toxic turn at 
positions 22 and 23 detected Aβ oligomers in 
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human AD brain (49) and induced pluripotent 
stem cells (50) as well as in AD mice (51,52).  
As mentioned above, an attempt to determine the 
Lys residues involved in the adduct formation by 
LC-MS-MS analysis gave disappointing results, 
possibly because of the extremely low amount 
and/or instability of the adducts.  Since the 
targeted Lys-residues (Lys16 and 28), not the Arg 
residue (Arg5), are incorporated in the 
intermolecular β-sheet region (Fig. 8), even a 
small amount of covalently-bonded adducts at the 
Lys residues of Aβ42 oligomers and/or 
protofibrils could inhibit the formation of Aβ42 
aggregates (fibrils) detected by the Th-T 
fluorescence.   
Recently, Bitan's group reported that the 
Lys-specific synthetic compound (molecular 
tweezer, CLR01) prevented the cytotoxicity and 
oligomerization of Aβ42 through non-covalent 
interaction in vitro (53) and in vivo (54).  Their 
subsequent study using Aβ42 mutants substituted 
at Lys16 or Lys28 with Ala revealed a key role 
for Lys residues in Aβ42-induced neurotoxicity 
rather than aggregation (55).  These reports did 
not contradict the results that the aggregates of 
double and triple mutants [K16,K28(nL)2-Aβ42 
and R5,K16,K28(nL)3-Aβ42] after 24-h of 
incubation were slightly less than that of 
wild-type Aβ42 in this study (Fig. 5F). 
R5nL-Aβ42 (~4 h) and K28nL-Aβ42 (~2 h) 
had the nucleation phase (Fig. 5A, C), while three 
Aβ42 mutants [K16nL-Aβ42, 
K16,K28(nL)2-Aβ42, and 
R5,K16,K28(nL)3-Aβ42] including the 
substitution of K16 with nL did not (Fig. 5B, D, 
E).  These mean that the aggregative ability of 
K16nL-Aβ42 seems to be more potent than that 
of K28nL-Aβ42.  Because Lys16 residue is 
located at a hydrophobic cavity in the β-sheet 
region (56), the substitution with norleucine 
without an amino group could enhance the 
hydrophobic interaction in Aβ42 aggregates, 
leading to passing the nucleation phase.  In 
contrast, Lys28 was involved in the formation of 
salt bridge between Asp23 and Lys28 for Aβ42 
aggregation (56).  These findings imply the 
different role of lysine resides at positions 16 and 
28 in Aβ42 aggregation, which might explain the 
difference of aggregative ability between K16nL- 
and K28nL-Aβ42.   
Notably, the nucleation phase of R5nL-Aβ42 
(~4 h) was partially longer than that of wild-type 
Aβ42 (~1 h) (Fig. 1B, F and 5A).  Since the 
flexibility of N-terminal region has been thought 
to be essential for aggregation of Aβ42 (56), the 
replacement of Arg5 with norleucine might retard 
the nucleation phase in wild-type Aβ42 
aggregation by increasing hydrophobic interaction.  
Moreover, given no nucleation phase of three 
Aβ42 mutants of Lys16, it is not surprising that 
(+)-taxifolin did not largely alter the aggregation 
properties of these mutants, because (+)-taxifolin 
could specifically target the elongation phase in 
wild-type Aβ42 aggregation, rather than the 
nucleation phase. 
LeVine et al. suggested preventive effects on 
Aβ42 aggregation by several dihydroxybenzoic 
acid isomers, in which 2,3- and 3,4-dihydroxy 
benzoic acids delayed the velocity of oligomer 
formation (57).  Fisetin, a quercetin analogue 
without the 5-OH group on the A-ring, also 
inhibited the aggregation of Aβ42 (58).  
Ushikubo et al. reported that 7-OH group on the 
A-ring is not involved in the anti-aggregative 
ability of flavonols (59).  These are consistent 
with our previous study on the structure-activity 
relationship of (+)-taxifolin (23).  On the other 
hand, lacmoid without a catechol moiety bound 
less-specifically to Aβ42 (60).  These findings 
together with the present results strongly support 
that flavonoids with vicinal hydroxyl groups on 
the B-ring could be indispensable to bind 
covalently with Aβ42 to suppress its aggregation.  
It is also reasonable that 3,4,5-trihydroxybenzoic 
acid, gallic acid (57) and 
3',4',5'-trihydroxyflavone (59) as well as 
dihydromyricetin (Figs. 6A) suppressed the 
aggregation of wild-type Aβ42.  In particular, 
the inhibitory activities of dihydromyricetin, 
(+)-taxifolin, myricetin, and quercetin were 
higher than those of morin, kampferol, and 
datiscetin (Fig. 6A), suggesting that the 
nucleophilic addition to the o-quinone moiety by 
the Lys residues of Aβ42 could contribute more 
significantly to the inhibition of Aβ42 
aggregation than the hydrophobic interaction.  
 11 
 
However, additional role of the A- and C-rings of 
catechol-type flavonoids in the suppression of 
Aβ42 aggregation is not negligible, since the 
inhibitory activity of catechol itself was low (61).   
Fink and colleagues previously proposed the 
contribution of interaction of Lys residues with 
the baicalein o-quinone to the inhibition of 
α-synuclein responsible for Parkinson's disease 
(45).  However, the underlying molecular 
mechanism cannot be fully explained by the 
oxidized baicalein because the aggregation of 
α-synuclein was inhibited by baicalein even under 
an anaerobic condition (45).  Quite recently, the 
oxidation product of EGCG was in part involved 
in remodeling the preformed fibrils of Aβ40 by 
EGCG (62). 
To the best of our knowledge, this is a first 
report that dihydromyricetin and datiscetin as well 
as (+)-taxifolin have anti-aggregative activity 
against Aβ42.  We also demonstrated that 
(+)-taxifolin could suppress the elongation phase 
in the aggregation of wild-type Aβ42, rather than 
the nucleation phase.  Seed extracts of Silybum 
marianum, known as silymarin, have long been 
used as an anti-hepatotoxic medicine without 
notable adverse effects (63), and in particular, are 
efficacious against damage induced by alcohol 
and disturbances in the function of the 
gastrointestinal tract (64).  Booth et al. showed 
that (+)-taxifolin was not toxic when given long 
term to albino rats (65).  Therefore, (+)-taxifolin 
may be a worthy candidate for AD therapeutics.  
Although some polyphenols [naringenin (66) and 
curcumin (67)] were reported to pass through the 
blood-brain barrier after oral administration, 
caution should be used because of the difference 
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Fig. 1.  Effects of auto-oxidation of (+)-taxifolin on its ability to inhibit Aβ42 aggregation and 
Met35 oxidation.  A, The structure of (+)-taxifolin.  B, The effect of sodium periodate (NaIO4), an 
oxidant, on Aβ42 aggregation estimated by Th-T tests.  Aβ42 (25 µM) was incubated with or without 
(+)-taxifolin (50 µM) and/or NaIO4 (100 µM) at 37 oC.  C, The ability of (+)-taxifolin to suppress the 
aggregation of Aβ42 under an anaerobic condition.  Aβ42 (25 µM) was incubated with or without 
(+)-taxifolin (50 µM) in vacuo at room temperature.  D, HPLC analysis of Aβ42 solution with the 
indicated treatment.  Aβ42 (25 µM) was incubated with or without (+)-taxifolin (50 µM) and/or NaIO4 
(100 µM) at 37 oC for 4 h.  An aliquot was centrifuged by 20,130 g at 4 oC for 10 min, and the 
supernatant was subjected to HPLC on a Develosil ODS UG-5 column under a gradient of 10-50% 
CH3CN containing 0.1% NH4OH for 40 min.  E, The effect of tris(2-carboxylethyl)phosphine 
hydrochloride (TCEP-HCl denoted as TCEP), a reductant, on Aβ42 aggregation.  Aβ42 (25 µM) was 
incubated with or without (+)-taxioflin (50 µM) and/or TCEP (100 µM) at 37 oC.  F, The aggregative 
ability of Aβ42 in the presence of Aβ42 seed and/or (+)-taxifolin, NaIO4.  Aβ42 (25 µM) was incubated 
with or without the seed (10 µg/mL) and/or (+)-taxifolin (50 µM), NaIO4 (100 µM) at 37 oC.  The data 
are presented as the mean ± s.e.m. (n = 8).  Th-T relative fluorescence was expressed as a percentage of 
the fluorescence for wild-type Aβ42 alone, whose maximum value was taken as 100%.   
 
Fig. 2.  Effects of auto-oxidation of (+)-taxifolin on the morphology of Aβ42 aggregates.  A, TEM 
images of Aβ42 aggregates after 48 h of incubation.  Aβ42 (25 µM) was treated with or without 
(+)-taxifolin (50 µM) and/or NaIO4 (100 µM) under an aerobic or anaerobic condition.  Scale bar = 200 
nm.  B, UV-visible spectra of (+)-taxifolin (50 µM) treated with Aβ42 (25 µM) in the presence of NaIO4 
(100 µM) or TCEP (100 µM) after incubation for 0, 4, 8, 24, and 48 h, respectively. 
 
Fig. 3.  Effects of auto-oxidation of (+)-taxifolin on its ability to prevent the transformation into 
the β-sheet structure of Aβ42 using CD spectrometry.  A-C, Aβ42 (25 µM) was incubated (A) 
without, with (+)-taxifolin (50 µM) in the (B) absence or (C) presence of NaIO4 (100 µM) at 37 oC for the 
period indicated.  D, E, Aβ42 (25 µM) was incubated (D) without or (E) with (+)-taxifolin (50 µM) in 
vacuo at room temperature for the period indicated.   
 
Fig. 4.  LC-MS analysis of Aβ42 treated with oxidized taxifolin.  A, The proposed structures of the 
adducts between oxidized taxifolin and Aβ42.  (Upper) Lys16, Lys28, and (lower) Arg5 in Aβ42 could 
attack the o-quinone of (+)-taxifolin, resulting in (left) Michael addition or (right) Schiff base formation 
with the indicated calculated mass.  B, LCMS-IT-TOF analysis of the Aβ42 solution treated with 
oxidized taxifolin.  After Aβ42 (25 µM) was incubated with (+)-taxifolin (50 µM) in the presence of 
NaIO4 (100 µM) at 37 oC for 4 h, an aliquot was subjected to the analysis. 
 
Fig. 5.  Effects of (+)-taxifolin on the aggregation of Aβ42 mutants substituted with norleucine 
(nL).  The aggregative ability of A, R5nL-Aβ42, B, K16nL-Aβ42, C, K28nL-Aβ42, D, 
K16,K28(nL)2-Aβ42, and E, R5,K16,K28(nL)3-Aβ42 in the presence of (+)-taxifolin was examined by 
Th-T assay.  Each Aβ42 mutant (25 µM) was incubated with or without (+)-taxifolin (50 µM) at 37 oC.  
The data are presented as the mean ± s.e.m. (n = 8).  Th-T relative fluorescence was expressed as a 
percentage of the fluorescence for Aβ42 mutant alone, whose maximum value was taken as 100%. 
*p<0.05 compared with Aβ42 mutant alone.  The time point without asterisk means no significant 
difference between Aβ42 mutant treated and untreated with (+)-taxifolin.  F, The comparison of 
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aggregative ability of Aβ42 mutants.  Th-T relative fluorescence of each mutant after incubation for 24 h 
was expressed as a percentage of the fluorescence for wild-type Aβ42 alone, whose maximum value was 
taken as 100%.  The data are presented as the mean ± s.e.m. (n = 8). 
 
Fig. 6.  Effects of flavanonols and flavonols on the aggregation of Aβ42.  A, The structures and IC50 
values of (upper) flavanonols and (lower) flavonols examined in this study.  The IC50 value was 
calculated from the inhibitory rate (%) of each flavonoid on Aβ42 aggregation after 24 h incubation using 
Th-T assay.  B, Aβ42 (25 µM) incubated with morin, kaempferol, or datiscetin (50 µM) in vacuo at 
room temperature.  Th-T relative fluorescence was expressed as a percentage of the fluorescence for 
Aβ42 alone, whose maximum value was taken as 100%. 
 
Fig. 7.  Effects of flavanonols and flavonols on the aggregation of Aβ42 mutants.  A, The 
aggregative ability of Aβ42 mutants (25 µM) incubated with a catechol-type flavanonol or flavonol (50 
µM) for 24 h estimated by Th-T tests.  The data are presented as the mean ± s.e.m. (n = 8).  Th-T 
relative fluorescence was expressed as a percentage of the fluorescence for each Aβ42 alone, whose value 
at 24 h was taken as 100%.  B, The aggregative ability of Aβ42 mutants (25 µM) treated with a 
non-catechol-type flavonol (50 µM) for 24 h, estimated by Th-T tests.  *p<0.05.  n.s. = not significant. 
 
Fig. 8.  Site-specific inhibitory mechanisms of Aβ42 aggregation by catechol-type flavonoids.  
Catechol-type flavanonols (e.g. (+)-taxifolin) or flavonols (e.g. quercetin) were oxidized to form 
corresponding o-quinones on B-ring, followed by the formation of adducts by Lys16 and Lys28 of Aβ42.  
Because Lys16 and Lys28 are incorporated in the intermolecular β-sheet region (8), Aβ42 aggregates 
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Supplemental Scheme S1.  Synthesis of (+)-taxifolin and trapping of taxifolin o-quinone.  A, Route 
of (+)-taxifolin synthesis.  Dihydrokaempferol and pinobanksin were synthesized in a similar manner to 
(+)-taxifolin using 4-hydroxybenzaldehyde or benzaldehyde in place of vanillin as a starting material.  B, 
Trapping of (±)-taxifolin o-quinone by using o-phenylendiamine to form the corresponding phenazine.  
 
Supplemental Fig. S1.  NMR spectra of 
13
C6-(+)-taxifolin.  A, 
1H NMR spectrum of 13C6-(+)-taxifolin.  
1H NMR (500 MHz, 295.2 K, acetone-d6, 7.7 mM) " 4.61 (1H, dd, J = 11.5, 3.0 Hz), 5.01 (1H, dq, J = 11.5, 
4.0 Hz), 5.95 (1H, d, J = 2.4 Hz), 5.99 (1H, d, J = 2.4 Hz), 6.98 (2H, dm, J = 157.0 Hz), 7.07 (1H, dm, J = 
157.0 Hz), 11.7 (1H, s).  B, 13C NMR spectrum of 13C6-(+)-taxifolin.  
13C NMR (500 MHz, 295.2 K, 
acetone-d6, 7.7 mM) " 73.2, 84.7, 96.1, 101.5, 115.9, 120.8, 129.9, 146.8, 164.2, 165.1, 168.2, 198.0. 
 
Supplemental Fig. S2.  Solid-state NMR spectra of A!42 aggregates associated with (+)-taxifolin.  
A, 1D 13C CP/MAS spectra.  A!42 labeled at Ala2, Ser8, Lys16, Val18, Phe19, and Phe20, in which only 
C! was labeled in Phe19 and Phe20, and 
13C6-(+)-taxifolin on the B-ring were used.  Molar ratio, A!42 : 
(+)-taxifolin = 1 :11.  B, 2D Covariance-processed DARR spectra at a mixing time of (left) 50 ms and 
(right) 500 ms.  In the spectrum at 50 ms, the distance between carbon atoms with cross peaks is 1.5-3.0 
Å, whereas at 500 ms it is 1.5-5.0 Å.  In the spectrum at 500 ms, intermolecular cross peaks were as weak 
as noise signals in the region framed by the line.  C, 2D FT-DARR spectra at mixing time of (left) 50 ms 
and (right) 500 ms.  The number of acquisition was 400 scans per increment. 
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